Abstract

DNA polymerase theta (Polθ)-mediated end-joining (TMEJ) repairs DNA double-strand breaks and confers resistance to genotoxic agents. How Polθ is regulated at the molecular level to exert TMEJ remains poorly characterized. We find that Polθ interacts with and is PARylated by PARP1 in a HPF1-independent manner. PARP1 recruits Polθ to the vicinity of DNA damage via PARylation dependent liquid demixing, however, PARylated Polθ cannot perform TMEJ due to its inability to bind DNA. PARG-mediated de-PARylation of Polθ reactivates its DNA binding and end-joining activities. Consistent with this, PARG is essential for TMEJ and the temporal recruitment of PARG to DNA damage corresponds with TMEJ activation and dissipation of PARP1 and PAR. In conclusion, we show a two-step spatiotemporal mechanism of TMEJ regulation. First, PARP1 PARylates Polθ and facilitates its recruitment to DNA damage sites in an inactivated state. PARG subsequently activates TMEJ by removing repressive PAR marks on Polθ.

Here the authors reveal a two-step spatiotemporal regulation of (Polθ)-mediated end-joining (TMEJ). First, PARP1 PARylates Polθ and facilitates its recruitment to the vicinity of DNA damage sites in an inactivated state. PARG subsequently activates TMEJ by removing repressive PAR marks on Polθ.

Details

Title
PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks
Author
Vekariya, Umeshkumar 1 ; Minakhin, Leonid 2 ; Chandramouly, Gurushankar 2 ; Tyagi, Mrityunjay 2 ; Kent, Tatiana 2 ; Sullivan-Reed, Katherine 1 ; Atkins, Jessica 1 ; Ralph, Douglas 2 ; Nieborowska-Skorska, Margaret 1 ; Kukuyan, Anna-Mariya 1 ; Tang, Hsin-Yao 3   VIAFID ORCID Logo  ; Pomerantz, Richard T. 2   VIAFID ORCID Logo  ; Skorski, Tomasz 4   VIAFID ORCID Logo 

 Temple University, Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Philadelphia, USA (GRID:grid.264727.2) (ISNI:0000 0001 2248 3398) 
 Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, USA (GRID:grid.415231.0) (ISNI:0000 0004 0577 7855) 
 The Wistar Institute, Proteomics and Metabolomics Facility, Philadelphia, USA (GRID:grid.251075.4) (ISNI:0000 0001 1956 6678) 
 Temple University, Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Philadelphia, USA (GRID:grid.264727.2) (ISNI:0000 0001 2248 3398); Temple University, Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Philadelphia, USA (GRID:grid.264727.2) (ISNI:0000 0001 2248 3398); Fox Chase Cancer Center, Nuclear Dynamics and Cancer Program, Philadelphia, USA (GRID:grid.249335.a) (ISNI:0000 0001 2218 7820) 
Pages
5822
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3078200170
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.